Axon Enterprise, Inc (NASDAQ:AXON) Shares Purchased by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. grew its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 18.5% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,816 shares of the biotechnology company's stock after buying an additional 752 shares during the period. Crossmark Global Holdings Inc.'s holdings in Axon Enterprise were worth $2,533,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of AXON. Brighton Jones LLC purchased a new position in Axon Enterprise during the fourth quarter worth $480,000. Proficio Capital Partners LLC purchased a new stake in shares of Axon Enterprise in the fourth quarter valued at $78,414,000. Dorsey & Whitney Trust CO LLC purchased a new stake in shares of Axon Enterprise in the fourth quarter valued at $244,000. AlphaQuest LLC grew its position in shares of Axon Enterprise by 255.5% in the fourth quarter. AlphaQuest LLC now owns 871 shares of the biotechnology company's stock valued at $518,000 after purchasing an additional 626 shares during the period. Finally, Daiwa Securities Group Inc. grew its position in shares of Axon Enterprise by 84.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 18,268 shares of the biotechnology company's stock valued at $10,857,000 after purchasing an additional 8,341 shares during the period. Hedge funds and other institutional investors own 79.08% of the company's stock.

Insider Activity at Axon Enterprise

In related news, Director Michael Garnreiter sold 5,913 shares of the firm's stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $760.00, for a total value of $4,493,880.00. Following the sale, the director owned 17,740 shares of the company's stock, valued at approximately $13,482,400. This trade represents a 25.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, President Joshua Isner sold 9,905 shares of the firm's stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $738.03, for a total value of $7,310,187.15. Following the completion of the sale, the president directly owned 298,809 shares in the company, valued at approximately $220,530,006.27. This trade represents a 3.21% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 44,642 shares of company stock worth $30,500,428 over the last quarter. 4.40% of the stock is owned by corporate insiders.

Axon Enterprise Stock Down 0.5%

AXON traded down $3.37 on Friday, reaching $729.62. The company's stock had a trading volume of 1,120,957 shares, compared to its average volume of 545,551. The stock has a market cap of $56.80 billion, a price-to-earnings ratio of 176.24, a price-to-earnings-growth ratio of 83.99 and a beta of 1.29. Axon Enterprise, Inc has a 1 year low of $279.02 and a 1 year high of $830.21. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.83 and a quick ratio of 2.62. The business's 50 day moving average is $752.67 and its 200 day moving average is $641.14.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The company had revenue of $603.63 million for the quarter, compared to the consensus estimate of $585.67 million. During the same quarter last year, the business posted $1.15 EPS. Axon Enterprise's quarterly revenue was up 31.3% compared to the same quarter last year. As a group, research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on AXON. The Goldman Sachs Group lifted their price objective on Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research report on Wednesday, May 14th. Bank of America lifted their price objective on Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a research report on Wednesday, June 4th. Barclays lifted their price objective on Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. Needham & Company LLC lifted their price objective on Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Finally, Wolfe Research initiated coverage on Axon Enterprise in a research report on Monday, July 7th. They set an "outperform" rating for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the company's stock. According to MarketBeat, Axon Enterprise has an average rating of "Moderate Buy" and an average target price of $699.55.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.